As a proliferation marker, the Ki-67 index is used clinically to determine the prognosis of cancer and evaluate its treatment, and it is of great importance to decision-making concerning the adjuvant treatment of early breast cancer [2]. Here, MKI67 is linked to breast carcinoma.